

## Special Issue

# Toxicokinetics in Renal Disease

### Message from the Guest Editor

The progressive replacement of conventional live attenuated and inactivated whole cell vaccines with new generation of subunit vaccines based in purified, recombinant, syntenic and nucleic acid-based vaccines (DNA or RNA) has generally reduced reactogenicity but also immunogenicity. Therefore, adjuvants and delivery systems are key components that are used to optimize and to enhance the efficacy of vaccines. The majority of known adjuvants have been empirically identified any are often associated with adverse reactions. Adjuvant-induced toxicity considerably limits their use in human and veterinary vaccines. The reduced immunogenicity of new vaccine antigens and the need for safer vaccines have increased the importance of identifying single, well-defined adjuvants with known molecular targets and mechanisms of action for rational vaccine design. This Special Issue focuses on current approaches and challenges to modulate the immune response with molecular adjuvants for vaccine improvement. This is a topic of intense current research in vaccinology.

---

### Guest Editor

Dr. Tony K. L. Kiang

Faculty of Pharmacy and Pharmaceutical Sciences, The University of Alberta, Edmonton, AB, Canada

---

### Deadline for manuscript submissions

closed (31 August 2024)



## Pharmaceutics

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.9  
CiteScore 7.9  
Indexed in PubMed



[mdpi.com/si/80098](https://mdpi.com/si/80098)

*Pharmaceutics*  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[pharmaceutics@mdpi.com](mailto:pharmaceutics@mdpi.com)

[mdpi.com/journal/  
pharmaceutics](https://mdpi.com/journal/pharmaceutics)





# Pharmaceutics

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.9  
CiteScore 7.9  
Indexed in PubMed



[mdpi.com/journal/  
pharmaceutics](https://mdpi.com/journal/pharmaceutics)



## About the Journal

### Message from the Editor-in-Chief

*Pharmaceutics* (ISSN 1999-4923) is an online open access journal on the science and technology of pharmaceuticals and biopharmaceuticals. The scientific community, the wider community and the general public have unlimited and free access to the content as soon as a paper is published; this open access to your research ensures your findings are shared with the widest possible audience. Please consider publishing your impressive work in this high quality journal. We would be pleased to welcome you as one of our authors.

---

### Editor-in-Chief

Prof. Dr. Patrick J. Sinko  
Department of Pharmaceutics, Ernest Mario School of Pharmacy,  
Rutgers University, Piscataway, NJ 08854, USA

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 14.9 days after submission; acceptance to publication is undertaken in 3.4 days (median values for papers published in this journal in the first half of 2024).